Research & Publications

TCT Special 2026: New Real-World Evidence for Paradise™ uRDN

November 9, 2026

Real-world outcomes*

Across diverse real-world clinical settings – from the GPS registry to a multicenter U.S. experience – Paradise uRDN demonstrated consistent performance, with meaningful and durable blood pressure reductions, procedural efficiency, and a strong safety profile.

*The content below summarizes scientific abstracts presented at TCT 2026 (Transcatheter Cardiovascular Therapeutics, October 2026). These abstracts represent preliminary data that have not yet been published in peer-reviewed journals. Data are presented for informational and scientific exchange purposes only. Individual patient results may vary. Sample sizes, study designs, and limitations should be considered when interpreting the findings.

TCT 2026 slide: Blood Pressure Outcomes Following Ultrasound Renal Denervation in Uncontrolled Hypertension, 12-Month Results from the Global Paradise System Registry, Felix Mahfoud, MD
12-month outcomes from the GPS Registry

Mahfoud et al.

In this real-world GPS Registry analysis (N=276), Paradise uRDN reduced office SBP by 19.5 mmHg among patients with complete 12-month follow-up and maintained a favourable safety profile. Similar blood pressure reductions were observed across subgroups, including patients aged ≥65 years and those with hypertensive crisis, diabetes, CKD stage 3a/3b, or heart failure.

TCT 2026 slide: Sustained Blood Pressure Reduction, High Clinical Success, and Favorable Safety Following Ultrasound Renal Denervation, A Multicenter US Experience, Behnam Tehrani, MD
U.S. experience and outcomes across multiple centers

Tehrani et al.

In U.S. real-world analysis of 238 patients, across 8 hospitals, Paradise uRDN demonstrated excellent procedural performance and safety. Among pooled patients with complete longitudinal follow-up, office BP reduction was 26.9 mmHg through 12 months.

Long-term durability

TCT 2026 slide: Durable Blood Pressure Reduction Through 4 Years Following Ultrasound Renal Denervation, Pooled Data from the RADIANCE Trial Program, Ajay J. Kirtane, MD, SM
Blood pressure outcomes through four years

Kirtane et al.

In the pooled RADIANCE pivotal clinical program (n=293), Paradise uRDN was associated with durable, clinically meaningful reductions in office systolic BP of 14.9 mmHg, with clinical benefit observed in 92% of patients at 4-year follow-up.

Hospital economic value

TCT 2026 slide: Economic Value of Ultrasound Renal Denervation, Pooled Analysis of the RADIANCE Trials, Surabhi Atreja, MD
Hospital-perspective economic analysis

Atreja et al.

In this conservative analysis of the pooled RADIANCE pivotal clinical program (n=509), the Paradise uRDN improved BP control and was associated with a lower cardiovascular event rate in patients with uncontrolled hypertension. These benefits were associated with lower hospitalization costs and fewer hospital days, supporting economic value in routine clinical practice.1

1. uRDN’s indication is for BP reduction, not cardiovascular event reduction. This information is provided as disease state awareness.

Patient-centric insights and care gaps

TCT 2026 slide: Sedation Strategy During Renal Denervation, Safety, Feasibility, and Patient Satisfaction
Patient-centered procedure under moderate sedation

Atreja et al.

Paradise uRDN under moderate sedation was well-tolerated (n=31), with low peri-procedural pain and high patient satisfaction. Moderate sedation with individualized analgesic protocols supported patient comfort, procedural efficiency, and rapid recovery.

TCT 2026 slide: Uncontrolled Hypertension and Outcomes in Patients Undergoing Staged PCI, Mount Sinai Fuster Heart Hospital
Hypertension undertreatment in patients with CAD

Mehran et al.

Among 2,285 hypertensive patients undergoing staged PCI, nearly 40% of hypertensive patients had uncontrolled BP at both index and staged PCI. Uncontrolled BP at staged PCI was linked to a 49% higher risk of 1-year adverse cardiovascular events, largely driven by MI. Treatment intensification was uncommon, identifying the interval between procedures as a missed opportunity for BP optimization.2

2. This disease-state information highlights an unmet need in hypertension management and does not constitute a claim regarding Paradise uRDN in this patient population.

TCT 2026 slide: Hypertension Phenotyping Based on Salt and Aldosterone Sensitivity, Implications for Precision Selection of Renal Denervation Candidates, Maria Carolina Delgado-Lelievre, MD
Outcomes across hypertension phenotypes

Delgado-Lelievre et al.

In this real-world cohort, including salt-sensitive and aldosterone-sensitive hypertension phenotypes (n=10), Paradise uRDN was associated with reductions in office and 24-hour ambulatory systolic BP. Improvements in nocturnal dipping suggested a beneficial effect on circadian BP regulation.